内臓痛覚(Visceral Pain):治療薬開発パイプライン動向(世界、2015年上半期版)

◆英語タイトル:Visceral Pain - Pipeline Review, H1 2015
◆商品コード:GMDHC6298IDB
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2015年2月18日
◆ページ数:52
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥220,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥440,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥660,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

当調査レポートでは、世界における内臓痛覚(Visceral Pain)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・内臓痛覚(Visceral Pain)の概要
・内臓痛覚(Visceral Pain)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・内臓痛覚(Visceral Pain)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・内臓痛覚(Visceral Pain)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・内臓痛覚(Visceral Pain)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Visceral Pain – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Visceral Pain – Pipeline Review, H1 2015’, provides an overview of the Visceral Pain’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Visceral Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Visceral Pain and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Visceral Pain
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Visceral Pain and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Visceral Pain products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Visceral Pain pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Visceral Pain
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Visceral Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Visceral Pain Overview 7
Therapeutics Development 8
Pipeline Products for Visceral Pain – Overview 8
Pipeline Products for Visceral Pain – Comparative Analysis 9
Visceral Pain – Therapeutics under Development by Companies 10
Visceral Pain – Therapeutics under Investigation by Universities/Institutes 11
Visceral Pain – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Visceral Pain – Products under Development by Companies 14
Visceral Pain – Products under Investigation by Universities/Institutes 15
Visceral Pain – Companies Involved in Therapeutics Development 16
Amorepacific Corporation 16
Astellas Pharma Inc. 17
GIcare Pharma Inc 18
Grunenthal GmbH 19
Hydra Biosciences, Inc. 20
Nektar Therapeutics 21
Neurim Pharmaceuticals Ltd 22
Trevena, Inc. 23
Visceral Pain – Therapeutics Assessment 24
Assessment by Monotherapy Products 24
Assessment by Target 25
Assessment by Mechanism of Action 27
Assessment by Route of Administration 29
Assessment by Molecule Type 31
Drug Profiles 32
ASP-7663 – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
GIC-1001 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
GIC-1002 – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
HC-030031 – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
NeuP-12 – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
NKTR-195 – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
PAC-14028 – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
piromelatine – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RO-656570 – Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Small Molecule to Block Nav1.9 Channel for Pain – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Small Molecules to Agonize Kappa Opioid Receptor for CNS Disorder – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
TRV-250 – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
URB-937 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Visceral Pain – Recent Pipeline Updates 48
Visceral Pain – Dormant Projects 49
Visceral Pain – Discontinued Products 50
Appendix 51
Methodology 51
Coverage 51
Secondary Research 51
Primary Research 51
Expert Panel Validation 51
Contact Us 51
Disclaimer 52

[List of Tables]
Number of Products under Development for Visceral Pain, H1 2015 8
Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Number of Products under Investigation by Universities/Institutes, H1 2015 11
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Development, H1 2015 13
Products under Development by Companies, H1 2015 14
Products under Investigation by Universities/Institutes, H1 2015 15
Visceral Pain - Pipeline by Amorepacific Corporation, H1 2015 16
Visceral Pain - Pipeline by Astellas Pharma Inc., H1 2015 17
Visceral Pain - Pipeline by GIcare Pharma Inc, H1 2015 18
Visceral Pain - Pipeline by Grunenthal GmbH, H1 2015 19
Visceral Pain - Pipeline by Hydra Biosciences, Inc., H1 2015 20
Visceral Pain - Pipeline by Nektar Therapeutics, H1 2015 21
Visceral Pain - Pipeline by Neurim Pharmaceuticals Ltd, H1 2015 22
Visceral Pain - Pipeline by Trevena, Inc., H1 2015 23
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Stage and Target, H1 2015 26
Number of Products by Stage and Mechanism of Action, H1 2015 28
Number of Products by Stage and Route of Administration, H1 2015 30
Number of Products by Stage and Molecule Type, H1 2015 31
Visceral Pain Therapeutics - Recent Pipeline Updates, H1 2015 48
Visceral Pain - Dormant Projects, H1 2015 49
Visceral Pain - Discontinued Products, H1 2015 50

[List of Figures]
Number of Products under Development for Visceral Pain, H1 2015 8
Number of Products under Development for Visceral Pain - Comparative Analysis, H1 2015 9
Number of Products under Development by Companies, H1 2015 10
Comparative Analysis by Clinical Stage Development, H1 2015 12
Comparative Analysis by Early Stage Products, H1 2015 13
Assessment by Monotherapy Products, H1 2015 24
Number of Products by Top 10 Targets, H1 2015 25
Number of Products by Stage and Top 10 Targets, H1 2015 25
Number of Products by Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 27
Number of Products by Top 10 Routes of Administration, H1 2015 29
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 30
Number of Products by Stage and Top 10 Molecule Types, H1 2015 31

【掲載企業】

Amorepacific Corporation
Astellas Pharma Inc.
GIcare Pharma Inc
Grunenthal GmbH
Hydra Biosciences, Inc.
Nektar Therapeutics
Neurim Pharmaceuticals Ltd
Trevena, Inc.

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 内臓痛覚(Visceral Pain):治療薬開発パイプライン動向(世界、2015年上半期版)(Visceral Pain - Pipeline Review, H1 2015)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆